In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

References

• Andrews PD. (2005). Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA. (2008). Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357–1364.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. (2004). Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25:1631–1639.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. (2008). Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639–1648.
   PubMed Web of Science ®Google Scholar
• Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ. (2003). Activation and overexpression of centrosome kinase BTAK/aurora-A in human ovarian cancer. Clin Cancer Res 9:1420–1426.
   PubMed Web of Science ®Google Scholar
• Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, Lin MH. (2010). Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 38:223–231.
   PubMed Web of Science ®Google Scholar
• Jeng YM, Peng SY, Lin CY, Hsu HC. (2004). Overexpression and amplification of aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065–2071.
   PubMed Web of Science ®Google Scholar
• Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M. (1999). Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160–1162.
   PubMed Web of Science ®Google Scholar
• Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Höög C, van Duin M, Gossen JA, Sassone-Corsi P. (2007). Differential functions of the aurora-B and aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 21:726–739.
   PubMed Web of Science ®Google Scholar
• Kimura M, Matsuda Y, Yoshioka T, Okano Y. (1999). Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274:7334–7340.
   PubMed Web of Science ®Google Scholar
• Kitzen JJ, de Jonge MJ, Verweij J. (2010). Aurora kinase inhibitors. Crit Rev Oncol Hematol 73:99–110.
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584–590.
   PubMed Web of Science ®Google Scholar
• Lentz KA. (2008). Current methods for predicting human food effect. AAPS J 10:282–288.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (1998). Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions. J Pharm Pharmacol 50:493–499.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2005). Interspecies Pharmacokinetic Scaling. Rockville, MD: Pine House Publishers.
   Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–479.
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–1359.
   PubMed Web of Science ®Google Scholar
• Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. (2009). Predicting pharmacokinetics of drugs using physiologically based modeling—application to food effects. AAPS J 11:45–53.
   PubMed Web of Science ®Google Scholar
• Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault Patel, VF, Geuns-Meyer S, Radinsky R, Kendall RL. (2010). Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 70:9846–9854.
   PubMed Web of Science ®Google Scholar
• Pollard JR, Mortimore M. (2009). Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 52:2629–2651.
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304–1311.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Singh BN, Malhotra BK. (2004). Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43:1127–1156.
   PubMed Web of Science ®Google Scholar
• Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M, Liu Z, Wang M, Guo L, Lu S, Wu M, Zhan Q. (2004). Overexpression of aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10:7304–7310.
   PubMed Web of Science ®Google Scholar
• Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603–611.
   PubMed Web of Science ®Google Scholar
• Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250–254.
   PubMed Web of Science ®Google Scholar